The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2018-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of $82,183.1 million in 2022.The Canada was the fastest growing country, with a CAGR of 4.7% over the 2018-22 period.
- Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of $69,916.7 million in 2022. This was followed by Canada and Mexico, with a value of $6,229.7 and $6,036.8 million, respectively.
- The US is expected to lead the generics industry in the NAFTA bloc, with a value of $82,184.5 million in 2027, followed by Canada and Mexico with expected values of $8,709.6 and $7,402.3 million, respectively.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market
- Leading company profiles reveal details of key generics market players’ NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume
- Compares data from the US, Canada and Mexico, alongside individual chapters on each country
Reasons to Buy
- What was the size of the NAFTA generics market by value in 2022?
- What will be the size of the NAFTA generics market in 2027?
- What factors are affecting the strength of competition in the NAFTA generics market?
- How has the market performed over the last five years?
- How large is the NAFTA generics market in relation to its regional counterparts?
Table of Contents
1 Introduction
2 NAFTA Generics
3 Generics in Canada
4 Macroeconomic Indicators
5 Generics in Mexico
6 Macroeconomic Indicators
7 Generics in The United States
8 Macroeconomic Indicators
9 Company Profiles
10 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Novartis AG
- Teva Pharmaceutical Industries Limited
- Viatris Inc.
- Apotex, Inc.
- Sun Pharmaceutical Industries Ltd
- Aurobindo Pharma Ltd
- Pfizer Inc.